Aliskiren: clinical experience and future perspectives of renin inhibition

Bibliography

• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003;361:1629-41
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. J Am Med Assoc 2003;289:2363-9
   PubMed Web of Science ®Google Scholar
• Oparil S, Haber E. The renin-angiotensin system. N Engl J Med 1974;291:381-401
   PubMedGoogle Scholar
• Dzau VJ. Tissue angiotensin and pathobiology of vascular disease, a unifying hypothesis. Hypertension 2001;37:1047-52
   PubMed Web of Science ®Google Scholar
• Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J Biol Chem 1990;265(36):22348-57
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32(3):387-92
   PubMed Web of Science ®Google Scholar
• Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001;87:10C-17C
   PubMed Web of Science ®Google Scholar
• Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24(2):243-56
   PubMed Web of Science ®Google Scholar
• Siragy HM, Xue C, Abadir P, Carey RM. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 2005;45:133-7
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368(9545):1449-56
   PubMed Web of Science ®Google Scholar
• Fisher ND, Hollenberg NK. Is there a future for renin inhibitors? Exp Opin Invest Drugs 2001;10:417-26
   PubMed Web of Science ®Google Scholar
• Lefevre G, Duval M, Poncin A. Direct micro-radio immunoassay of the new renin inhibitor CGP 60536. J Immunoassay 2000;21(1):65-84
   PubMed Web of Science ®Google Scholar
• Allikmets K. Aliskiren (Speedel). Curr Opin Investig Drugs 2002;3(10):1479-82
   PubMedGoogle Scholar
• Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308(4):698-705
   PubMed Web of Science ®Google Scholar
• Danser AH, Derkx FH, Schalekamp MA, et al. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998;16:853-62
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular response to renin. J Clin Invest 2002;109:1417-27
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ichihara A, Kaneshiro Y, et al. Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J Am Soc Nephrol 2007;18(7):1989-92
   PubMedGoogle Scholar
• Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000;7:493-504
   PubMed Web of Science ®Google Scholar
• Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-8
   PubMed Web of Science ®Google Scholar
• El Amrani AI, Menard J, Gonzales MF, Michel JB. Effects of blocking the angiotensin II receptor, converting enzyme and renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol 1993;22:231-9
   PubMedGoogle Scholar
• Novartis Pharmaceutical Corporation. Tekturna® (aliskiren tablets): US prescribing information. East Hanover, NJ: Novartis Pharmaceutical Corporation; 2007
   Google Scholar
• Vaidyanathan S, Jin Y, Schiller H, Jensen C. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmacol Toxicol 2005;97(Suppl 1):239
   Google Scholar
• Ganten D, Wagner J, Zeh K, et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992;89:7806-10
   PubMed Web of Science ®Google Scholar
• Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76
   PubMed Web of Science ®Google Scholar
• Shagdarsuren E, Wellner M, Braesen JH, et al. Complement activation in angiotensin II induced organ damage. Circ Res 2005;97:716-24
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8
   PubMed Web of Science ®Google Scholar
• Oh BH, Mitchel J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63
   PubMed Web of Science ®Google Scholar
• Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006;29:997-1005
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20
   PubMed Web of Science ®Google Scholar
• Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Philipp T, Guerediaga J, et al. Aliskiren-based therapy lowers blood pressure more efficiently than hydrochlorothiazide-based therapy in patients with hypertension. J Clin Hypertens 2007;9(Suppl A):A182
   Google Scholar
• Anderson K, Weinberger MH, Egan B, et al. Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double blind trial. J Am Coll Cardiol 2007;49(Suppl 1):A371
   Google Scholar
• Strasser RH, Puig JG, Farsang C, et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007;21(10):780-7
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49(5):1047-55
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarow SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double blind trial. Lancet 2007;370:221-9
   PubMed Web of Science ®Google Scholar
• O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007;49:276-84
   PubMed Web of Science ®Google Scholar
• Uresin Y, Taylor A, Kilo C, et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Clin Hypertens 2006;24(Suppl 4):S82(P-269)
   Google Scholar
• Drummond W, Munger MA, Rafique Essop M, et al. Antihypertensive efficacy of the oral renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007;9(10):742-50
   PubMedGoogle Scholar
• Messerli FH, Re RN. Do we need yet another blocker of the renin-angiotensin system? J Am Coll Cardiol 2007;49(11):1164-5
   PubMed Web of Science ®Google Scholar
• Weir MR, Bush C, Anderson DR, et al. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1(4):264-77
   PubMed Web of Science ®Google Scholar
• Aldeman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8
   PubMedGoogle Scholar
• Li P, Chappell MC, Ferrario CM, et al. Angiotensin (1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997;29:394-400
   PubMed Web of Science ®Google Scholar
• Dellipizzi AM, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin (1-7). Br J Pharmacol 1994;111:1-3
   PubMed Web of Science ®Google Scholar
• Freeman EJ, Chisolm GM, Ferrario CM, et al. Angiotensin (1-7) inhibits vascular smooth muscle growth. Hypertension 1996;28:104-8
   PubMed Web of Science ®Google Scholar
• Mahon JM, Carr RD, Nicol AK, Henderson IW. Angiotensin (1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens 1994;12:1377-81
   PubMed Web of Science ®Google Scholar
• Iyer SN, Chappell MC, Averill DB, et al. Vasodepressor actions of angiotensin (1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998;31:699-705
   PubMed Web of Science ®Google Scholar
• Luque M, Martin P, Martell N, et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996;14:799-805
   PubMed Web of Science ®Google Scholar
• Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue angiotensin systems. Regul Pept 1993;43:1-20
   PubMed Web of Science ®Google Scholar
• Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007;20:587-97
   PubMed Web of Science ®Google Scholar
• Menard J, Azizi M. The difficult conception, birth, and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007;25:1775-82
   PubMed Web of Science ®Google Scholar